Establishing routine early on helps proactively manage adverse effects associated with CDK4/6 inhibitors, says Kimberly ...

Panelists discuss the critical role of patient education and multidisciplinary coordination in managing immunotherapy side ...

Panelists discuss the importance of vigilant, patient-centered monitoring for metastatic melanoma patients with high disease ...

Paolo Tarantino, MD, PhD, explains that the chemotherapy-related toxicities from an ADC are more likely to limit dosage for ...

The addition of retifanlimab to chemotherapy increased progression-free survival in patients with advanced squamous cell ...

Panelists discuss how a 48-year-old fitness instructor with ALK-rearranged stage IV lung cancer and bone metastases was ...

While CIML natural killer immunotherapy can result in infection-like reactions, required prior chemo may cause infections, ...

Panelists discuss updated MonumenTAL-1 trial data demonstrating high response rates and prolonged survival with ...

Panelists discuss updated safety findings from GPRC5D-targeted bispecific therapy in relapsed/refractory multiple myeloma, ...

Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says ...

A quality-adjusted time without symptoms or toxicity analysis identified better outcomes for patients with RCC treated with belzutifan vs everolimus.